Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial

This study is testing a combination of immunotherapy (atezolizumab), anti-angiogenic therapy (bevacizumab), and liver-directed procedures (TACE and HAIC) for patients with unresectable advanced liver cancer (hepatocellular carcinoma, or HCC) that cannot be surgically removed. **You may be eligible if...** - You have been diagnosed with unresectable advanced-stage hepatocellular carcinoma (liver cancer) - Your liver function is reasonably preserved (Child-Pugh A or B) - Your general health is adequate (ECOG 0–1) - You have adequate blood counts (white blood cells, platelets, and hemoglobin above specified thresholds) **You may NOT be eligible if...** - You have serious underlying heart, lung, or kidney disease - You have a second primary cancer - You have a known contraindication to atezolizumab or bevacizumab (e.g., severe autoimmune disease, active bleeding risk) Talk to your doctor to see if this trial is right for you.